Assessment of the Xpert assay among new pulmonary tuberculosis suspects with and without diabetes mellitus

Citation: Deshmukh S, Atre S, Ramchandra, Chavan A, Raskar S, Mave V, Gupte N, Gaikwad S, Sahasrabudhe Tushar, Barthwal M, Kakrani A, Kagal A, Gupta A, Bharadwaj R, Pradhan N, Dharmshale S, Golub J. Assessment of the Xpert assay among new pulmonary tuberculosis suspects with and without diabetes mellitus. Int J Tuberc Lung Dis. 1 Jan 2020: 24(1); 11-117(5). doi: https://doi.org/10.5588/ijtld.19.0239

Access full article:

https://www.ingentaconnect.com/content/iuatld/ijtld/2020/00000024/00000001/art00017;jsessionid=6pppm0b097kpg.x-ic-live-03

SETTING:
Pune and Pimpri-Chinchwad Municipal Corporation area, Maharashtra State, India.

OBJECTIVE:
To assess the sensitivity and specificity of the Xpert® MTB/RIF assay among adults with suspected pulmonary tuberculosis (PTB) and with or without diabetes (DM).

DESIGN:
As part of a prospective cohort study, we screened 2359 adults presumed to have PTB with no history of TB. All individuals underwent testing for two sputum smears, culture, Xpert, glycated haemoglobin and fasting blood sugar. We calculated sensitivity and specificity of Xpert by comparing it with TB sputum culture result as a gold standard.

RESULTS:
Among screened individuals, 483 (20%) were diagnosed with DM and 1153 (49%) with pre-DM; 723 (31%) had no DM. Overall sensitivity of Xpert was 96% (95%CI 95–97) and specificity was 91% (95%CI 89–93). Xpert sensitivity was significantly higher among DM group (98%) than in the ‘No DM' (95%; P < 0.01) and pre-DM (96%; P < 0.05) groups. Among sputum smear-negative individuals, Xpert sensitivity was higher in the DM group than in the No DM (92% vs. 82%; P = 0.054) and pre-DM group (92% vs. 82%; P = 0.037).

CONCLUSION:
High sensitivity and specificity of Xpert underscores the need for its rapid scale up for the early detection of TB in settings with a high dual burden of TB and DM.

Categories

CRS
Topics

Clinical Trials

Identification of Biomarkers That Can Predict Progression...

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More